update on buyback and NSE listing
6 Likes
1 Like
2 Likes
Can anyone validate the company’s interpretation of the Net Worth criteria is correct? On a consol basis they have met the threshold since FY21 but due to the merger last year the clock gets reset? That doesn’t make much sense.
2 Likes
I personally feel NSE listing and buyback are least important in the larger context. It’s good to see that 3B has clarified that it intends to utilize the funds for potential acquisitions. If the likely acquisition creates value coupled with organic growth, 3B stock will continue to trend higher. Irrespective of listing on one or two exchanges.
9 Likes
Basically no buyback and no NSE listing for another 3 years.
2 Likes
I was comparing the 2024 catalogue vs the 2023 catalogue:
- 2024 has a much more expanded product portfolio
- PGx is new in 2024
- Glad to see BRCA mutation test kits under TruNGS
–
–
–
–
17 Likes
Did anyone attend the AGM? If you did, please share your notes
Couldn’t. Sad to see that the company is not publishing the transcript of the AGM discussions or the analysts meet. Holding on to my investment on the basis of the positive outlook of the CMD’s address, 50% growth expectations for Manchester unit, 20% overall growth and the hope that any challenge on margins may be offset by topline growth… others please comment on the outlook after AGM. Also if the company is able to sell the agro division on a decent price and go for a little debt ( D/E < 0.5) in the long run it can have up to a Rs. 500 Cr. pool for potential acquisition. Am I right?
6 Likes
Summary of 52nd AGM
I hope you find it useful.
dr.vikas
7 Likes